
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.

Your AI-Trained Oncology Knowledge Connection!


One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
![“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/a69f69efca1ade2e100fbb9cdf798d49ea5a0f94-2966x1684.png?w=350&fit=crop&auto=format)
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.